• 1
    Blancher C, Harris AL. The molecular basis of hypoxia response pathway: tumour hypoxia as a therapy target. Cancer Metast Rev. 1998; 17: 187194.
  • 2
    Semenza GL, Agani F, Feldser D, et al. Hypoxia, HIF-1, and the pathophysiology of common human disease. Adv Exp Med Biol. 2000; 475: 123130.
  • 3
    Huang LE, Gu J, Schau M, Bunn F. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA. 1998; 95: 79877992.
  • 4
    Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci USA. 1991; 88: 56805684.
  • 5
    Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001; 61: 29112916.
  • 6
    Koukourakis MI, Giatromanolaki A, Skarlatos J, et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res. 2001; 61: 18301832.
  • 7
    Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumors and survival. Br J Cancer. 2001; 85: 881890.
  • 8
    Noyes RW, Hertig AT, Rock J. Noyes RW, Hertig AT, Rock J. Dating the endometrial biopsy. Fertil Steril. 1950; 1: 325.
  • 9
    Longacre TA, Kempson RL, Hendrickson MR. Endometrial hyperplasia, metaplasia and carcinoma. In: FoxH, WellsM, editors. Haines and Taylor obstetrical and gynaecological pathology, 4th ed. New York: Churchill Livingstone, 1995: 421510.
  • 10
    Silverberg SG, Kurman RJ. Endometrial carcinoma. In: SilverbergSG, KurmanRJ, editors. Tumours of the uterine corpus and gestational trophoblastic disease. Atlas of tumor pathology. Third series, fasicle 3. Washington DC: Armed Forces Institute of Pathology, 1992: 4789.
  • 11
    Talks KL, Turley H, Gatter KC, et al. The expression and distribution of the hypoxia inducible factors HIF-1a and HIF-2a in normal human tissues, cancers and tumor associated macrophages. Am J Pathol. 2000; 157: 411421.
  • 12
    Sivridis E, Giatromanolaki A, Koukourakis M, Anastasiadis P. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchows Arch. 2001; 438: 470477.
  • 13
    Giatromanolaki A, Sivridis E, Koukourakis M, Harris AL, Gatter KC. bcl-2 and p53 expression in Stage I endometrial carcinoma. Anticancer Res. 1998; 18: 36893694.
  • 14
    Turley H, Scott PA, Watts VM, Bicknell R, Harris AL, Gatter KC. Expression of VEGF in routinely fixed material using a new monoclonal antibody VG1. J Pathol. 1998; 186: 313318.
  • 15
    Brekken RA, Huang X, King SW, Thorpe PE. Vascular endothelial growth factor as a marker of tumor endothelium. Cancer Res. 1998; 58: 19521959.
  • 16
    Giatromanolaki A, Sivridis E, Brekken R, et al. The angiogenic “vascular endothelial growth factor/fll-1(KDR) receptor” pathway: prognostic and therapeutic implications. Cancer. 2001; 92: 25692577.
  • 17
    Fox SB, Moghaddam A, Westwood M, et al. Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study. J Pathol. 1995; 176: 183190.
  • 18
    Sivridis E, Giatromanolaki A, Koukourakis M, Bicknell AL, Harris AL, Gatter KC. Thymidine phosphorylase expression in endometrial carcinomas. Clin Exp Metast. 1999; 17: 445450.
  • 19
    Sivridis E, Giatromanolaki A, Koukourakis MI, Georgiou L, Anastasiadis P. Patterns of episialin/MUC1 expression in endometrial carcinomas and prognostic relevance. Histopathology. 2002; 40: 92100.
  • 20
    Harris AL. von-Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) receptor therapy. Oncologist. 2000; 5 (Suppl 1): 3236.
  • 21
    Mazure NM, Chen EY, Laderoute KR, Giaccia AJ. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia inducible factor-1 transcriptional element. Blood. 1997; 90: 33223331.
  • 22
    Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 1999; 59: 39153918.
  • 23
    Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 2000; 14: 391396.
  • 24
    Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effect of ionizing radiation. Cancer Res. 1999; 59: 33743378.
  • 25
    Sawada N, Ishikawa T, Sekiguchi F, Tanaka Y, Ishitsuka H. X-ray irradiation induces thymidine phosphorylase and enhances the efficacy of capecitabine (Xeloda) in human xenografts. Clin Cancer Res. 1999; 5: 29482953.
  • 26
    Koukourakis MI, Giatromanolaki A, Fountzilas G, Sivridis E, Gatter KC, Harris AL. Angiogenesis, thymidine phosphorylase and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res. 2000; 6: 381389.
  • 27
    Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1a in common human cancers and their metastases. Cancer Res. 1999; 59: 58305835.
  • 28
    Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res. 2000; 60: 46934696.
  • 29
    Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst. 2001; 93: 309314.
  • 30
    Zhong H, Chiles K, Feldser D, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000; 60: 15411545.
  • 31
    Zelzer E, Levy Y, Kahana C, Shilo BZ, Rubinstein M, Cohen B. Insulin induces transcription of target genes through the hypoxia-inducible factor HIF1alpha/ARNT. EMBO J. 1998; 17: 50855094.
  • 32
    Bausero P, Ben-Mahdi M, Mazucatelli J, Bloy C, Perrot-Applanat M. Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen and hypoxia. Am J Physiol Heart Circ Physiol. 2000; 279: 20332042.
  • 33
    Giatromanolaki A, Sivridis E, Koukourakis MI, Georgoulias V, Gatter KC, Harris AL. Intratumoral angiogenesis: a new prognostic indicator for Stage I endometrial adenocarcinomas? Oncol Res. 1999; 11: 205212.
  • 34
    Sivridis E, Giatromanolaki A, Anastasiadis P, et al. Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. J Pathol. 2002; 196: 416422.
  • 35
    Wiesener MS, Turley H, Allen WE, et al. Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha. Blood. 1998; 92: 22602268.
  • 36
    Konerding MA, Steinberg F, van Ackern C, Budach V, Streffer C. Vascular patterns of tumors: scanning and transmission electron microscopic studies on human xenografts. Strahlenther Onkol. 1992; 168: 444452.
  • 37
    Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res. 1999; 59: 37763782.